Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

EORTC and ESSO project provides opportunity to do prospective study on liver metastasis surgery

Is it possible to cure patients with unresectable colorectal liver metastases? Are complex surgeries safe for patients with extensive metastatic disease? How can we monitor and improve the quality of these surgical strategies? How can we improve surgical care for patients through research?

15 Sep 2015

Study shows WATS3D biopsy can help overcome limitations of histopathological assessment of esophageal precancer

Prevention of Esophageal Adenocarcinoma, the most rapidly growing cancer in the US and one of the most fatal, relies upon the detection of precancerous cells sampled during an endoscopy.

14 Sep 2015

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Myriad Genetics, Inc. today presented two posters on its myPlan Lung Cancer prognostic test at the International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer being held in Denver, Colo.

9 Sep 2015

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma.

9 Sep 2015

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

Nearly all advanced esophageal cancers harbor genetic mutations that can be targeted with emerging drug therapies, according to a new study published in The Oncologist on September 2, 2015.

3 Sep 2015

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

21 Aug 2015

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

14 Aug 2015

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease spreads — metastasizes — in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer, which strikes nearly 50,000 people in the U.S. each year and has only a 5 percent survival rate five years after diagnosis.

11 Aug 2015

Penn research reveals additional pathway for origin of colon cancer

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process.

6 Aug 2015

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

30 Jul 2015

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.

30 Jul 2015

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.

21 Jul 2015

Canadian and Israeli researchers meet to discuss underlying mechanisms that drive pancreatic cancer

Leading Canadian and Israeli scientists gathered at the Hebrew University of Jerusalem's Faculty of Medicine to attend a forum on pancreatic cancer research and help dedicate the Alex U. Soyka Pancreatic Cancer Research Project.

18 Jun 2015

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection.

17 Jun 2015

NGS mutational testing can help detect patients with Barrett's esophagus

Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus. Although periodic surveillance for cancer is recommended for BE patients, these examinations may fail to identify pre-cancerous dysplasia and early cancers.

9 Jun 2015

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.

1 Jun 2015

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

1 Jun 2015

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Researchers from University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine will present data from several new studies, including a study evaluating a potential novel combination treatment for cancer patients with advanced solid tumors and a first-of-its-kind analysis of gene mutations in small cell lung cancer (SCLC), at the 51st American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Adenocarcinoma News and Research

Further Reading

EORTC and ESSO project provides opportunity to do prospective study on liver metastasis surgery

Study shows WATS3D biopsy can help overcome limitations of histopathological assessment of esophageal precancer

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

New study suggests potential use of targeted therapies for two subtypes of esophageal cancer

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Scientists identify molecular partnership that may help explain how pancreatic cancer spreads

Penn research reveals additional pathway for origin of colon cancer

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Intraoperative fluorescent imaging detects lung adenocarcinoma during pulmonary resection

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

Canadian and Israeli researchers meet to discuss underlying mechanisms that drive pancreatic cancer

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

NGS mutational testing can help detect patients with Barrett's esophagus

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

PharmaEngine files NDA with Taiwan FDA for MM-398 to treat post-gemcitabine metastatic pancreatic cancer

ASCO 2015: UH Seidman Cancer Center researchers present data from several new studies

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News